Monogram Orthopaedics

Future of Joint Replacement

Monogram Orthopaedics

Future of Joint Replacement

Austin, TX
Health Tech
Monogram is a medical technology company ushering in the future of joint reconstruction. Monogram Orthopaedics is developing a product solution architecture to enable mass personalization of orthopedic implants by linking 3D printing and robotics via automated digital image analysis algorithms. We are designing our state-of-the-art surgical robot with the aim of mitigating the risks of poor placement, fracture, and subsidence to give surgeons confidence that they can install implants that fit every patient - perfectly.

$8,393,762

raised
5,441
Investors
$89.9M
Valuation
$7.52
Price per Share
$250.80
Min. Investment
Common
Shares Offered
Equity
Offering Type
$34.9M
Offering Max
Reg A+
Offering

$8,393,762

raised
5,441
Investors
$89.9M
Valuation
$7.52
Price per Share
$250.80
Min. Investment
Common
Shares Offered
Equity
Offering Type
$34.9M
Offering Max
Reg A+
Offering

Rewards

Get rewarded for investing more into Monogram Orthopaedics:

$5,000+
Investment
5% Bonus Shares
Invest $5,000 and receive 5% Bonus Shares on your investment
$10,000+
Investment
10% Bonus Shares
Invest $10,000 and receive 10% Bonus Shares on your investment

Monogram has not yet applied for or obtained FDA approval for our novel Monogram products and sales of novel Monogram products may not commence until approval is received.

Reasons to Invest

  • World-class team with a track record of execution: led by a team of experts in robotics and medical technology, and advised by surgeon consultants from institutions such as Columbia and Icahn School of Medicine.
  • Expect revenues in 2021: we expect to start generating revenue from sales of implants in 2021 and have signed strategic contracts with two Monogram distributors and recruited the Senior Director of US Sales from our manufacturer to support early sales efforts.
  • Already raised $16.7M from 6,793 investors: We have been through 3 successful financing rounds and continue to execute.
  • Established product-market fit: the leading orthopedic robot on the market (technology from a startup acquired in 2013) outsells it's next largest competitor over 12-to-1 with 87% share.  Our VP of Engineering helped develop that technology. Together with our team's support, we want to build the future of robotics.
  • Novel technology for massive growing market: The joint replacement market is approximately $19.6BN, with over 1 million knee replacements per year. We believe we will be one of the first to market with our technology and eight patent filings.

Overview


Our mission is to make orthopedics personal

Monogram Orthopedics will use the latest in robotic, AI, and 3-D printing technologies to make orthopedic care personal. Monogram will try and make every design and development decision by focusing on what we think will most benefit patients and improve clinical outcomes (note: this is based on management opinion and has not been demonstrated in live patients).


Four companies currently dominate the multi-billion dollar joint reconstruction market with an 82% combined share in knees (source). Many companies fail to penetrate this market, as many believe change isn’t possible.

*above image is computer generated and not yet available for commercial sales

With what we believe to be innovative robotic and implant technologies, we will try to improve the accuracy of implant placement, and we hope thereby improve patient outcomes at a lower cost (note: this is based on management opinion and has not been demonstrated in live patients). Our priority is clinical benefits for patients and true patient satisfaction. We believe patients and surgeons alike deserve better.  Monogram's goal is to try and lead what we believe to be the future of joint reconstruction.

The Problem


One size fits none approach leaves patients behind

Up to 10% of all knee and 15% of hip replacements fail annually (source).  These failures are in part because the technology is inherently inefficient and subject to surgeon error.  Joint replacement technology has, in many ways, remained the same for 40 to 50 years. Often crude and finicky instruments like saws and jigs are used to prepare the bone for geometric and rigid generic implants that don't accurately fit.  Insertions are often eyeballed and subject to proper surgeon execution. Management believes we may be able to design the Monogram workflow for efficiency and accuracy by leveraging the technical manufacturer specifications of our robot arm. 

Furthermore, four large companies dominate the market, leaving little room for innovation. This consolidation hurts patients and surgeons by limiting patient options and slowing the pace of technological progress.  

Traditional surgeries are also highly inefficient, with underutilized instruments and unused implants that add to the treatment burden. Monogram aims to reduce the required instrumentation needed to perform joint replacement procedures and streamline inventory requirements. We believe this will be especially beneficial as the market shifts to Ambulatory Surgery Centers.

Our primary focus is the wellbeing of our future patients.  Revisions and failures are serious and far too frequent. We plan our cases for execution with a state-of-the-art surgical robot.  We believe the combined improvements to the robot and implants could potentially benefit patient outcomes and mitigate risk - this is based on management opinion and has not been demonstrated in live patients.

Patients and surgeons need more comprehensive, clinical focused solutions that truly fit their needs.

The Solution


The next-gen 3D implant solution

We design implants for active patients that want to restore their quality of life. Management believes our integrated solution may eliminate the cost and improve efficiency in the operating room by reducing instrumentation and optimizing the cut path execution.


We have optimized our next-generation joint replacement solution with a state-of-the-art robot.

Monogram is committed to developing patient-optimized orthopedic implants, inserted with a surgical robot for unparalleled precision. Our navigated surgical robot relies on a CT-based pre-operative plan and has more reach (approximately 4.2 feet), with 7-degrees of freedom. (source, pg 5)

Our fully-personalized system breaks the barriers of traditional, cemented implant procedures that rely on manual instrumentation. While the underlying technologies are highly sophisticated and complex, the workflow remains straightforward and capital efficient.

GIF 1

GIF 2

GIF 3

GIF 4

GIF 5

“By failing to plan, you are planning to fail.” – Benjamin Franklin

The Market


A $19.6 billion joint replacement market in need of innovative disruption

The joint replacement market is currently at $19.6BN (source) with hip and knee replacements being the most common. The knee replacements market is $8.7 billion (source). Despite the market's significant size, innovation has plateaued because just four large companies dominate. Monogram's first addressable market will be total knee replacements, with almost 1 million knee replacements performed in the United States annually (source). Some market estimates project there will be nearly 3.5 million annual Total Knee Replacement procedures by the year 2030 (source)

By 2027, approximately 50% of all knee procedures will be robotic, up from 11% in 2019 (source). In the United States, we currently cement 92% of knees versus only 3% of hips. We believe that surgeons prefer uncemented or "press-fit" implants (source) and management believes press-fit knee adoption represents one of the most significant growth opportunities in orthopedics. Monogram is developing a next generation uncemented knee designed that we expect will benefit from these macro trends. 

A significant driver of press-fit implant utilization (the type of implant Monogram is developing) is patient demographics.  Improved low wear plastics make joint replacements more suitable for younger patients. In particular, patients less than 65 years of age represent the fastest-growing population of TKR recipients, expected to account for more than 50% of knee replacement procedures by the year 2030 (source).  We are designing the Monogram implants to meet the demands of younger active patients.

Another tectonic market shift that we see driving the adoption of technologies is the growing outpatient trend to Ambulatory Surgery Centers.  In January 2018, the Centers for Medicare & Medicaid Services (CMS) removed knee replacement procedures from the inpatient-only list, allowing procedures to be conducted on an outpatient basis.  


Across the country, the average cost for an inpatient knee replacement is $30,249, compared to $19,002 in the outpatient setting (source)- we believe these cost savings will drive significant volumes away from high volume hospitals. 


Our Traction


Significant capital raised, eight patents filed, and trusted surgeon advisors to support product-market fit

Monogram has raised $16.7 million with 6,793 trusted shareholders. We are actively deploying this capital to develop our novel orthopedic technologies and the operating and sales infrastructure needed to support their distribution. Monogram has recruited five practicing surgeons to support our development and validation efforts and provide practical user input. We aim for our products to be suitable for both the surgeon user and our patients.  

To date, we have signed contracts with two distributors that will market Monogram to select geographies.  We expect to generate revenue from licensed implants in 2021. We have a newly completed 350 square foot Monogram cadaver lab based in Austin, Texas, along with a team of 16 full-time employees. We have filed eight patents related to our proprietary technologies, as well as a Freedom-to-Operate (FTO) search for Monogram's knee design with a robotic surgical approach. 

Our internal cadaver lab allows our engineers to develop and validate many of our products more efficiently and economically.  In parallel, the lab supports our sales channels by allowing our team to demonstrate the product pipeline and share the vision with distributors and surgeons with live cadaveric surgeries before FDA approval.

*future events are anticipated based on full funding of the company in this offering or from other sources, and there is no guarantee the company will be able to meet those future milestones

What We Do


Implants that perfectly match every patient

At Monogram, we believe that there is a better, less-invasive way to treat patients. We combine 3D printing and robotics with CT-based pre-operative planning to enable mass personalization of the next generation of orthopedic implants.

Implant Design, Reimagined

The process starts with a CT scan, which is the starting point for personalization. From the CT scan, we can create an accurate patient-specific 3D models of the bony anatomy. By building a customized implant for every patient, we believe we may be able to more fully restore anatomical function and mitigate clinical risks (note: this has not been demonstrated in live patients). We believe bone conserving highly stable press-fit implants that rely on natural biologic fixation will improve patient outcomes and usher in the future of orthopedics (note: this is based on management opinion and has not been demonstrated in live patients).

GIF 6

3D Printed Implants

Unlike conventional, expensive, labor-intensive manufacturing, Monogram will deliver highly personalized implants efficiently at scale by leveraging state-of-the-art manufacturing methods and 3D printing. 


All Monogram implants will undergo rigorous validations and testing to ensure the highest industry quality standards. Monogram has conducted extensive mechanical strength testing that tries to simulate the rigorous ISO strength testing standards mandated by the FDA (we have not yet submitted our implants for the ISO strength tests mandated by the FDA and we can make no assurances that our implants will pass such testing). Our implants will be a biocompatible medical-grade titanium alloy (Ti64) with a chemical composition corresponding to ISO 5832-3, ASTM F1472, and ASTM B348.

GIF 7

Robotic Milling Cavity Technology

Monogram takes surgical robotics to the next level. There are currently no CT-based, navigated robots that actively execute bone cuts without user-initiated movements. Monogram aims to be the first company to release such a robot. 


Our goal is to combine groundbreaking software with world-class hardware, delivering an integrated robotic system that addresses major clinical concerns today - cost, time, and a lack of efficient control.

GIF 8

The Business Model


Goal to Lower cost and try to improve accuracy and efficiency

We are developing the implant and robotics in parallel, but we plan to de-risk the commercialization with discrete FDA submissions. We have entered into a distribution agreement for an FDA approved total knee system, specific components of which we intend to integrate into our novel knee system for future release. As part of this agreement, we recruited the Senior Director of US Sales from the manufacturer to support early sales efforts. 

Monogram intends to secure distribution relationships for these existing products before releasing our novel products as a Phase I release. 

Monogram has not yet applied for or obtained FDA approval for our novel Monogram products and sales of novel Monogram products may not commence until approval is received.

In the second phase, Phase II, we intend to commercialize our patient-specific implants inserted manually (the "Gen 2" implant) as a discrete FDA submission. We hope to drive sales through the distribution channels established during the first phase, Phase I. In Phase III, we will release our surgical robot.

Monogram will have two primary revenue streams; a revenue stream from the sale of capital equipment and a revenue stream from our consumable products' sale.  We expect to price our implants like the national ASP, and we will undercut competitive pricing for our capital equipment.

In the future, we intend to develop applications for additional clinical applications, including partial knees and hips, and we are investigating applications for shoulders, spine, and extremities.  

How We Are Different


A fully integrated medical solution never seen in the market before

The Monogram management team sees a clear growth opportunity for an efficient and strategically priced navigated robotic surgical system that relies on advanced imaging like a CT-scan. We will design the Monogram implants and robotic system to have a good product-market fit for the growing demographic of patients age 64 and younger. 


The current market consolidation also presents opportunities for Monogram. The size and operational complexity of our large competitors, with so many stakeholders and product lines, can make it difficult for them to advance disruptive innovations efficiently. Monogram sees a greenfield opportunity for a surgical robot that uses advanced imaging to actively and efficiently mill cavities for a perfect fit with 3D-designed implants. We believe we are on track for it to be the first of its kind in the market if we are successful.

In our testing conducted with our research partners, our implants appear to outperform leading generic equivalents by, in some variations, a considerable margin.  We think we can design more stable bone conserving implants that rely on natural biologic fixation through an innovative design approach, and we think we can leverage the high accuracy manufacturer specifications of the robotic arm for accurate bone preparation and customization of the implant design and surgical plan to the specific patient.  Personalization also minimizes the inventory and instrumentation, which eases the burden on hospitals and ASCs.  

In summary, we provide a fully integrated, personalized orthopedic solution that combines custom bone preparation with optimized 3D printed implants that has never been done before.  From the trend to ASCs to a younger patient demographic to increased robotic utilization, the underlying market dynamics all bode favorably.

The Vision


Commercialize a differentiated surgical robot for multiple orthopedic applications

The total orthopaedic market is over $53BN annually. Our initial focus is total knee replacements followed by partial knee and hip replacements - we are actively investigating shoulders, ankles, and spine. We expect to generate revenue in 2021.

Our vision is to improve the standard of care in orthopedics with personalized technology solutions. With a differentiated, navigated surgical robot that prepares the bone for clinically differentiated press-fit orthopedic implants, we will be able to make implants more stable that preserve the bone and rely on natural biologic fixation.

Monogram has executed two distribution agreements thus far. We expect to generate revenue in 2021, and we anticipate continuing to grow our sales network as we gain traction. We will leverage our dedicated cadaver lab, housed in our 4,000 square foot Austin facility, to demo our product pipeline to continue to build our distributor and surgeon relationships.

OUR LEADERSHIP


Led by surgeons and Medtech executives with engineering and finance expertise

Our founder and Chief Medical Officer, Dr. Douglas Unis, is a board-certified attending orthopedic surgeon for the Mount Sinai Health System. Dr. Unis, along with Caltech graduate and CEO - Benjamin Sexson, CFA, lead a team of experts in surgical robots and implant design. Our VP of Engineering is Kamran Shamaei, Ph.D., who worked with Think Surgical Inc. on the TSolution One Robot and supported the development of Monarch robots at Auris Health Inc. Chris Scifert, Ph.D., the former Director of Engineering for Orchid Orthopedic Solutions Design, one of the largest manufacturers of implants globally, is running the development of our implants and instruments.

Monogram has recruited five practicing surgeons to support our development and validation efforts and provide practical user input. These surgeons include doctors from The Orthopedic Specialty Center of Northern California, Orthopaedic Specialists of Austin and Columbia University.

Monogram currently employs 16 full-time employees and is actively contracting with four consulting firms with significant subject matter expertise.

Why Invest


Take medical robotics to the next level

The reasons to invest are straightforward; we have a proprietary technology for products that don't currently exist for a large and growing $19.6BN joint replacement market. We have protected our products with multiple IP filings that we know have a product-market fit because the only similar technology on the market has an 87% market share. While we have ambitious goals, we have successfully raised $16.7M to date and have assembled a differentiated team with the experience needed to execute. We believe we will be early to market with a solution with the potential to change the standard of care in orthopaedics.

Many companies are trying various solutions to compete - imageless registration, small footprints, portability, and cost. We think they are overthinking the proven solution and will struggle with adoption. We believe that the market desperately needs a viable alternative and none currently exists. 

By investing in Monogram, you will be supporting an experienced team to develop the future of orthopedics, which we believe is patient optimized 3D printed implants designed for high accuracy robotic placement. With our eight patents pending, a leadership team of experts in medical and surgical technology, and a highly differentiated solution fit for the growing $19.6BN joint replacement market, we can minimize surgical risks and restore patients to their active lifestyles.

We hope you will join the adventure and invest in the future of orthopedics!

Monogram has not yet applied for or obtained FDA approval for our novel Monogram products and sales of novel Monogram products may not commence until approval is received.


AN OFFERING STATEMENT REGARDING THIS OFFERING HAS BEEN FILED WITH THE SEC. THE SEC HAS QUALIFIED THAT OFFERING STATEMENT, WHICH ONLY MEANS THAT THE COMPANY MAY MAKE SALES OF THE SECURITIES DESCRIBED BY THE OFFERING STATEMENT. IT DOES NOT MEAN THAT THE SEC HAS APPROVED, PASSED UPON THE MERITS OR PASSED UPON THE ACCURACY OR COMPLETENESS OF THE INFORMATION IN THE OFFERING STATEMENT.


THE OFFERING CIRCULAR THAT IS PART OF THAT OFFERING STATEMENT CAN BE FOUND HERE.


THE OFFERING MATERIALS MAY CONTAIN FORWARD-LOOKING STATEMENTS AND INFORMATION RELATING TO, AMONG OTHER THINGS, THE COMPANY, ITS BUSINESS PLAN AND STRATEGY, AND ITS INDUSTRY.  THESE FORWARD-LOOKING STATEMENTS ARE BASED ON THE BELIEFS OF, ASSUMPTIONS MADE BY, AND INFORMATION CURRENTLY AVAILABLE TO THE COMPANY’S MANAGEMENT.  WHEN USED IN THE OFFERING MATERIALS, THE WORDS “ESTIMATE,” “PROJECT,” “BELIEVE,” “ANTICIPATE,” “INTEND,” “EXPECT” AND SIMILAR EXPRESSIONS ARE INTENDED TO IDENTIFY FORWARD-LOOKING STATEMENTS, WHICH CONSTITUTE FORWARD LOOKING STATEMENTS. THESE STATEMENTS REFLECT MANAGEMENT’S CURRENT VIEWS WITH RESPECT TO FUTURE EVENTS AND ARE SUBJECT TO RISKS AND UNCERTAINTIES THAT COULD CAUSE THE COMPANY’S ACTUAL RESULTS TO DIFFER MATERIALLY FROM THOSE CONTAINED IN THE FORWARD-LOOKING STATEMENTS.  INVESTORS ARE CAUTIONED NOT TO PLACE UNDUE RELIANCE ON THESE FORWARD-LOOKING STATEMENTS, WHICH SPEAK ONLY AS OF THE DATE ON WHICH THEY ARE MADE.  THE COMPANY DOES NOT UNDERTAKE ANY OBLIGATION TO REVISE OR UPDATE THESE FORWARD-LOOKING STATEMENTS TO REFLECT EVENTS OR CIRCUMSTANCES AFTER SUCH DATE OR TO REFLECT THE OCCURRENCE OF UNANTICIPATED EVENTS.

Updates

Cut Test Teaser!

9 days ago

We completed our first end-to-end system cut test run through the guidance application.  You can watch a teaser here (https://youtu.be/u7NUejgMPsE)!

Monogram has implemented a pipeline that includes auto-segmentation of patient scans and surgical planning for robotic execution with our guidance application. We successfully ran our first end-to-end system test, including registration, robotic execution, and implant placement, all within the guidance application.

The next steps include many system optimizations and known enhancements, but we now largely have the architecture in place to accelerate those efforts. This cut test was the culmination of an incredible amount of work and coordination between teams.

Our next goal is to run our first-time studies within 2-3 sprints (targeting the end of August). We have highly ambitious cut time goals, and our team is pushing this extremely hard.

We look forward to hopefully sharing more in-depth information and video when the timing is right! Thank you all for your incredible support.

Keep following for more updates on how Monogram uses high precision, patient-specific implants with state-of-the-art robotics to improve patient outcomes. Support our mission to shape the future of joint replacement and click here to learn more and invest in Monogram through our page on StartEngine.

This investment is speculative, illiquid, and involves a high degree of risk, including the possible loss of your entire investment.  

Monogram Reaches $8M in Investments!

14 days ago

We are pleased to announce that our crowdfunding campaign on StartEngine recently surpassed $8M in funding.

Right now, when you invest, you can receive up to 10% bonus shares!

Investors that invest at least $5,000 in this offering will receive a 5% bonus, and investors that invest at least $10,000 will receive a 10% bonus on their investment.

Join thousands of investors worldwide by investing in Monogram's mission to disrupt this $19.6b market by combining high precision, patient-specific implants with state-of-the-art robotics to improve patient outcomes.

Monogram Starts Generating Revenue with First TKA Procedure

4 months ago

Monogram is pleased to announce that on Monday, March 22nd, 2021, we completed our first Total Knee Arthroplasty ("TKA") procedure as a company and will now be generating revenue. Facilitating the requirements needed to perform our first case is a significant accomplishment for Monogram and the culmination of a tremendous team effort.  

Monogram is now:

  • HIPAA compliant
  • has implemented an ERP system with lot tracing
  • has secured implant component supply
  • has established distribution relationships
  • has implemented several critical insurance policies
  • has run its first cadaver lab in its Austin facility

"Our philosophy has always been to build an operating business as quickly as possible, which means much more than having competitive products," said CEO Ben Sexson. "The basic infrastructure and systems required to support and scale growth in our highly regulated market are demanding and cannot be overlooked. Pulling all the pieces together to facilitate sales in such a highly regulated market is a major first step towards our goal of building a real orthopedic company.  We believe the first dollars of revenue are always the hardest."

Monogram has not provided sales guidance but would like the investors to calibrate expectations appropriately. "Aggressively driving sales requires a significant working capital investment, and the most compelling components of our product pipeline remain in development and our focus," said CEO Ben Sexson. "We want to build a company that can scale at the appropriate time. The goal right now is forward-thinking, and we are focused on the long-term.  In the long-term, innovative products that improve patient lives are what matter to us most." 


 Monogram expects to continue generating revenues and remains optimistic about its ongoing growth prospects.

AMA with Surgeon Founder Doug Unis!

4 months ago

We are always looking for ways to engage with our community.  We get many clinical questions. We thought it would be a great idea to allow our shareholders or individuals interested in Monogram to engage with our founder surgeon, Dr. Unis, and ask him any clinical questions you may have…for example...


  • Get his thoughts on stem cell treatments and research

  • Get his thoughts on when to get knee replacements

  • What to expect and how to improve your outcomes

  • Get his input on surgical techniques and his preferences

  • Get insights on what to ask your surgeon


This “Ask Me Anything” event will be an open opportunity for you to engage in a constructive conversation.  Our CEO, Ben Sexson, will also be available to help answer any questions about Monogram.


If you are interested in participating, please register below:

Thursday, 8 April 2021, 6:00 PM ET
Registration link: https://event.webinarjam.com/channel/monogram_ama

Monogram Passes $5M in Investments!

4 months ago

We just passed the $5,000,000 mark! Thank you to all of our investors so far for your support!

Don't forget that if you have already invested, you can invest multiple times during a campaign; it's not just a one-time investment!


Monogram Invited to Present at Wavemaker Labs Webinar March 10th!

5 months ago

Registration Link: http://bit.ly/3ustHwZ

Details: Wednesday, March 10th @ 10:00 AM Pacific Time (US and Canada)


Monogram Executes Strategic License of Unicondylar Knee Replacement Implant

5 months ago

Monogram is pleased to announce it has successfully executed a license agreement for an FDA-approved Unicondylar Knee Arthroplasty ("UKA") implant design from an established orthopedic manufacturer. Monogram intends to prioritize the launch of total knee and partial knee robotic applications.    

"The orthopedic market today is too siloed. Knee teams optimize knee products. Hip teams optimize hip products. Spine products are a completely different focus altogether. After the fact, large organizations try to force-fit platform technologies into these siloes," said CEO Ben Sexson. "Elon Musk explains this organization problem perfectly here. Monogram is building an orthopedic platform technology. We believe an orthopedic robot capable of addressing multiple clinical applications with a single-arm simplifies the capital equipment sales process with hospitals and will be massively differentiated. Integrating partial knees and other products into our robotic platform is critical for this."

Monogram's strategy is to develop a single, highly robust robotic platform technology that can address clinical opportunities across significant orthopedic applications, for example, knees (both total and partial), hips, shoulders, ankles, and spine. Monogram expects to begin developing its partial knee application when it enters V&V testing on its total knee application.

"If you look at Mako and their success, they started with partial knees, and after Stryker acquired them, they launched the total knee application in 2015," said Chief Medical Officer Dr. Doug Unis. "To compete with Mako, at a minimum, we will need robotic prep for both a total knee and a partial knee. Longer-term, we plan on addressing hips and other markets."

Monogram Passes $3.7M in Investments!

5 months ago

We just passed the $3,700,000 mark! Thank you to all of our investors so far for your support!

Don't forget that if you have already invested, you can invest multiple times during a campaign; it's not just a one-time investment!


Monogram to Present at OTC Markets Regulation A+ Investor Conference - Register now!

6 months ago

Monogram will be speaking Thursday, February 11, 2021, @ 11:30 AM ET at the OTC Markets Regulation A+ Investor Conference.  The presentation is 30 minutes and will include a management Q&A.

Here is the registration link here




Monogram Executes First Hospital Contract: Expect Revenues as early as First Quarter 2021

6 months ago

Monogram is pleased to announce that it has executed a Product Purchase Agreement with its first significant hospital institution.  The company expects it could begin placing implants in patients and generating revenue as early as the first quarter of 2021 (although cautions that Covid-19 and unforeseen market factors could impact timing).     

"Being accepted by the value analysis committee of a major hospital institution is a significant milestone for our company," said CEO Ben Sexson.  "We expect to begin generating revenues very soon.  We continue to execute on our strategic initiatives, and we are extremely pleased with the progress of our product pipeline and our pace of growth.  Our goal is to become a competitor in the ortho space as quickly as possible."


Monogram management looks forward to sharing our continued progress and is thankful for our shareholders without whom this progress would not have been possible.

Monogram Passes $3M in Reservations! Will be last chance to reserve!

6 months ago

We just passed the $3,000,000 mark!


If you are interested, reserve your shares now before this Test The Waters period closes!  Our investment minimum is only $250.79.

AND...


Right now, you can become eligible for bonus shares just for indicating interest in an investment.  For a limited time, during our “Testing The Waters” period (which we’re in now), you can become eligible to get 10% bonus shares when you invest just for indicating your interest in an investment now (not actually investing).


BUT...


This bonus will only be available during our Testing The Water period. We aren’t sure yet how long this period will last, but it will be a limited time, so we recommend joining sooner rather than later.


Please note that even if you do not make a reservation, you can still be eligible to receive Bonus Shares by investing at least $5,000 once we open for investments.  Reserving” shares is simply an indication of interest. There is no binding commitment for investors that reserve shares in this manner to ultimately invest and purchase the shares reserved of the company, or to purchase any shares of the company whatsoever. 

Monogram Passes $1.5M in Reservations! Limited Time Bonus!

7 months ago

Big news!  We just passed the $1,500,000 mark!


If you are interested, reserve your shares now before this Test The Waters period closes!  Our investment minimum is only $250.79.

AND...


Right now, you can become eligible for bonus shares just for indicating interest in an investment.  For a limited time, during our “Testing The Waters” period (which we’re in now), you can become eligible to get 10% bonus shares when you invest just for indicating your interest in an investment now (not actually investing).


BUT...


This bonus will only be available during our Testing The Water period. We aren’t sure yet how long this period will last, but it will be a limited time, so we recommend joining sooner rather than later.


Please note that even if you do not make a reservation, you can still be eligible to receive Bonus Shares by investing at least $5,000 once we open for investments.

Show More Updates End of Updates

Comments ({{profileCtrl.startup.comments_count}} total)

{{profileCtrl.newComment.body.length}}/2500
Please sign in to post a comment.
Please use Updates for communications.
{{ profileCtrl.commentsLoading ? 'Loading...' : 'Show More Comments' }}